Altering Adrenergic Signaling and Cardiac Function in Transgenic Mice
The ability to maintain and manipulate mouse embryos in vitro, perfected over the last decade, has launched the expanding field of transgenic experimentation models. With the successful insertion of foreign genes into the mouse genome, important in vivo transgenic models have emerged in several venues of biomedical research, which allows for a broader understanding of pathological conditions. Transgenic mice permit investigation of the consequences of a protein’s overexpression in specific tissues. In addition, the loss of function of a protein or enzyme in a given organ can be examined by overexpression of an inhibitor peptide or a dominant-negative mutant. Elimination of a protein from all tissues can also be achieved by gene disruption techniques. These approaches are well suited to study the physiological roles of cellular proteins.
KeywordsAdenylyl Cyclase Adrenergic Receptor Inverse Agonist Adrenergic Signaling Transgenic Manipulation
Unable to display preview. Download preview PDF.
- 10.Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: Desensitization of β-Adrenergic receptor function. FASEB 1990;4:2881–2889.Google Scholar
- 18.Pitcher JA, Fredericks ZL, Stone WC, Premont RT, Stoffel RH, Koch WJ, Lefkowitz RJ. Phosphatidylinositol-4,5-bisphosphate (PIP2)-enhanced G-protein-coupled receptor kinase (GRK) activity: Location, structure, and regulation of the PIP2 binding site distinguishes the GRK subfamilies. J Biol Chem 1996;271:24907–24913.PubMedCrossRefGoogle Scholar
- 19.Pitcher JA, Touhara K, Payne ES, Lefkowitz RJ. Pleckstrin homology domain-dedicated membrane association and activation of the beta-adrenergic receptor kinase requires coordinate interaction with Gβγ subunits and lipids. J Biol Chem 1995;270:11709–11710.Google Scholar
- 29.Bristow MR, O’Connel JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, Deitchman D, Anderson JL. Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemie cardiomyopathy. Bucindolol Investigators. Circulation 1994;89:1632–1642.Google Scholar